This inventor holds 1 USPTO granted patent. Top assignee: Cellectis Ab. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Karolina Åkesson in Cardiac Stem Cell Research
Introduction
Karolina Åkesson is a prominent inventor based in Gothenburg, Sweden. She has made significant contributions to the field of cardiac stem cell research. Her work focuses on the development of multipotent cardiac precursor cells derived from human blastocyst-derived stem cells.
Latest Patents
Karolina Åkesson holds a patent for a novel population of multipotent cardiac precursor (MCP) cells. This patent describes methods for the preparation of these cells and their use for in vitro testing. The MCP cells exhibit unique characteristics, including a characteristic morphology and growth patterns. They grow as clusters of small, round, and phase-bright cells, with individual cells measuring between 5-20 µm in diameter. Each cluster can consist of 2-500 cells, forming loosely adherent clumps. The MCP cells also have a relatively high nucleus-to-cytoplasma ratio, ranging from 1:2 to 1:64 of the total cell volume. Furthermore, these cells are non-contracting, which is a notable feature in their application.
Career Highlights
Karolina Åkesson is associated with Cellectis AB, a company known for its innovative approaches in genetic engineering and cell therapy. Her work at Cellectis AB has positioned her as a key figure in advancing cardiac stem cell research.
Collaborations
Karolina collaborates with notable colleagues, including Caroline Améen and Peter Sartipy. Their combined expertise contributes to the ongoing research and development in the field of cardiac precursor cells.
Conclusion
Karolina Åkesson's innovative work in the field of cardiac stem cell research highlights her contributions to science and medicine. Her patent on multipotent cardiac precursor cells represents a significant advancement in the understanding and application of stem cell technology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile